ATTACHMENT B

Amendments to the Claims

Please cancel claims 26-28 without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A pseudopeptide having general formula I

$$P - NH - \underset{\displaystyle R_1}{\underset{|}{CH}} - CO - NH - \underset{\displaystyle R_2}{\underset{|}{C(R_3)}} - CO - Asn - N(R_4R_5)$$

I

wherein:

P denotes a protecting group or a hydrogen atom,

R_1 denotes:

a phenylmethyl radical wherein the phenyl nucleus is substituted in the para position by $-OPO_3H_2$, phosphonomethyl, phosphonomonofluoromethyl or phosphonodifluoromethyl radical or

a ~~naphthylemethy~~ naphthylmethyl radical which may be substituted in the 4 position by $-OPO_3H_2$, phosphonomethyl, phosphonomono- or phosphonodifluoromethyl radical, each of these radicals also being optionally substituted by one or more substituents selected from among the C_1 to C_4 alkyl or C_1 to C_4 alkoxy groups and/or one or more halogen atoms,

R_2 denotes:

a phenylmethyl or ~~naphtylmethyl~~ naphthylmethyl or cyclohexylmethyl radical, 2- or 3-pyridinylmethyl, substituted at the para or meta position of the ring

by -OPO_3H_2, C_1 to C_2 phosphonoalkyl group, phosphonomonofluoromethyl, phosphonodifluoromethyl, ~~$-OPO_3H_2$~~ $-PO_3H_2$, phosphinate, ~~$-So_3H$~~ $-SO_3H$ sulfonomethyl, -CO_2H, carboxymethyl, carboxymethyloxy, malonyl, 2-(dicarboxy)ethyl, 2-malonyloxy, 5-tetrazolyl or 5-tetrazolylmethyl radical or

a radical alkyl of the type $(CH_2)_n$ (wherein n = 3 or 4) substituted in end position by a -OPO_3H_2, C_1 to C_2 phosphonoalkyl, preferably phosphonomonofluoromethyl and phosphonodifluoromethyl, phosphonate, phosphinate, sulfonate, sulfonomethyl, carboxylate, carboxymethyl, carboxymethyloxy, malonyl, 2-malonyloxy, 2-dicarboxyethyl, 5-tetrazolyl or 5-tetrazolylmethyl radical,

R_3 denotes a straight chain or branched C_1 to C_4 alkyl group or an alkylcycloalkyl group having a C_3 to C_6 cycloalkyl,

R_4 and/or R_5 denote:

a hydrogen,

a straight chain or branched C_1 to C_6 alkyl group

a C_1 to C_6 arylalkyl group wherein aryl denotes a phenyl or naphtyl nucleus optionally substituted by one or more hydroxyl groups, or

an aminohexanoic chain followed by the sequences RQIKIWFQNRRMKWKK (SEQ ID NO: 1), IRQPKIWFPNRRKPWKK (SEQ ID NO: 2), Cys-S-S-Cys-RQIKIWFQNRRMKWKK (SEQ ID NO: 3) and Cys-S-S-Cys-IRQPKIWFPNRRKPWKK (SEQ ID NO: 4) derived from Antennapedia or pharmaceutically acceptable salts thereof.

2. (Currently Amended) The ~~pseudoeptide~~ pseudopeptide according to claim 1, wherein:

P denotes an RCO or ROCO group where R denotes a C_{1-4} aminoalkyl or C_{1-4} aminophenylalkyl,

R_1 denotes a phenylmethyl group substituted in the para position by a substituent selected from among OPO_3H_2, $CH_2PO_3H_2$, $CHFPO_3H_2$ and $CF_2PO_3H_2$,

R_2 denotes a phenylmethyl group substituted in the meta or para position by $-OPO_3H_2$, C_1 to C_2 phosphonoalkyl group, phosphonomonofluoromethyl, phosphonodifluoromethyl, phosphonate, phosphinate, $-SO_3H$, sulfonomethyl, $-CO_2H$, carboxymethyl, carboxymethyloxy, malonyl, 2-(dicarboxy)ethyl, 2-malonyloxy, 5-tetrazolyl or 5-tetrazolylmethyl radical,

R_3 denotes a C_1 to C_4 alkyl group,

R_4 and/or R_5 denote a hydrogen atom, an alkyl $(CH_2)_n$-CH_3 or $(CH_2)_n$-Ar group wherein Ar denotes a phenyl or α or β-naphthyl which may or may not be substituted and n is between 0 and 5 and pharmaceutically acceptable salts thereof.

3. (Previously Presented) The pseudopeptide according to claim 1, wherein:

R_1 denotes a phenylmethyl group having $-OPO_3H_2$ group in the para-position,

R_2 denotes a phenylmethyl group having, in the para- or meta-position, a group selected from the group consisting of a phosphate, phosphonomethyl, 2-malonyloxy or $(CH_2)_nCO_2H$ group wherein n is equal to 0 or 1,

R_3 denotes a C_1-C_4 alkyl group, and

R_4 and R_5 both represent a hydrogen atom and the pharmaceutically acceptable salts thereof.

4. (Previously Presented) The pseudopeptide according to claim 1 selected from the group consisting of:

- mAZ-pTyr-(αMe)pTyr-Asn-NH_2
- mAZ-pTyr-(αMe)pTyr-Asn-Aha-Antennapedia
- mAZ-Pmp-(αMe)pTyr-Asn-NH_2
- mAZ-pTyr-(αMe)Phe(COOH)-Asn-NH_2
- mAZ-pTyr-(αMe)Phe(CH_2-COOH)-Asn-NH_2
- mAZ-pTyr-(αMe)Pmp-Asn-NH_2
- mAZ-pTyr-(αMe)F_2Pmp-Asn-NH_2
- mAZ-pTyr-(αMe)Phe(PO_3H_2)-Asn-NH_2
- mAZ-pTyr-(αMe)Phe (PO_3 H_2)-Asn-Aha-Antennapedia.

5-21. (Cancelled)

22. (Previously Presented) A pseudopeptide compound corresponding to general formula II



II

wherein:

P denotes a protecting group or a hydrogen atom,

R_3 denotes a straight chain or branched C_1 to C_4 alkyl group or an alkylcycloalkyl group having a C_3 to C_6 cycloalkyl,

R_4 and/or R_5 denote

a hydrogen,

a straight chain or branched C_1 to C_6 alkyl group

a C_1 to C_6 arylalkyl group wherein aryl denotes a phenyl or naphtyl nucleus optionally substituted by one or more hydroxyl groups, or

an aminohexanoic chain followed by the sequences RQIKIWFQNRRMKWKK (SEQ ID NO: 1), IRQPKIWFPNRRKPWKK (SEQ ID NO: 2, Cys-S-S-Cys-RQIKIWFQNRRMKWKK (SEQ ID NO: 3) and Cys-S-S-Cys-IRQPKIWFPNRRKPWKK (SEQ ID NO: 4), derived from Antennapedia,

P_1' is mono or bis-(S-acyl-2-thioethyl) phosphate and/or mono or bis-(acyloxymethyl) phosphate group wherein the term acyl denotes a tert-butylcarbonyl or isopropylcarbonyl or acetyl group; or

mono is bis-(s-acyl-2-thioethyl) phosphate and/or mono or bis-(acyloxymethyl) phosphate group wherein the term acyl denotes a tert-butylcarbonyl or isopropylcarbonyl or acetyl group; or

P_2' is mono or bis-(S-acyl-2-thioethyl) phosphate and/or mono or bis-(acyloxymethyl) phosphonomethyl groups wherein the term acyl denotes a tert-butylcarbonyl or isopropylcarbonyl or acetyl group; or

mono or bis-(S-acyl-2-thioethyl) phosphonomethyl and/or mono or bis-(acyloxymethyl) phosphononmethyl groups wherein the term acyl denotes a tert-butylcarbonyl or isopropylcarbonyl or acetyl group,

mono or bis-(S-acyl-2-thioethyl) phosphonate and/or mono or bis-(acyloxymethyl) phosphonate group wherein the term acyl denotes a tert-butylcarbonyl or isopropylcarbonyl or acetyl group, or

in the form of a carbonxylate of:

arylalkyl where the term aryl denotes a benzene nucleus and the term alkyl denotes a straight or branched carbon chain having 1 to 3 carbon atoms;

morpholinyl alkyl – (CH_2)n (NC_4H_8O);

piperidinyl alkyl –$(CH_2)_n(NC_5H_{10})$ optionally substituted by and OH, CO_2H, CO_2R' where R' is a straight or branched alkyl chain which may or may not contain a benzyl or phenyl group;

piperazinylalkyl – $(CH_2)_n(NC_4H_8NH)$ optionally substituted by (-N-C_4H_8-NR") where R" denotes an alkyl chain containing 1 to 6 carbon atoms, a benzyl group or a phenyl group, wherein n is between 1 and 3.

23. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 1~~, in an amount effective to inhibit proliferation of tumor cells~~.

24. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 1, selected from the group consisting of :

- mAZ-pTyr-(αMe)pTyr-Asn-NH_2
- mAZ-pTyr-(αMe)pTyr-Asn-Aha-Antennapedia
- mAZ-Pmp-(αMe)pTyr-Asn-NH_2
- mAZ-pTyr-(αMe)Phe(COOH)-Asn-NH_2
- mAZ-pTyr-(αMe)Phe~~(C_2-COOH)~~(CH_2-COOH)-Asn-NH_2
- mAZ-pTyr-(αMe)Pmp-Asn-NH_2
- mAZ-pTyr-(αMe)F_2Pmp-Asn-NH_2
- mAZ-pTyr-(αMe)Phe(PO_3H_2)Pmp-Asn-NH_2
- mAZ-pTyr-(αMe)Phe(PO_3H_2)-Asn-Aha-Antennapedia.

25. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 22~~, in an amount effective to inhibit proliferation of tumor cells~~.

26-28. (Canceled)

29. (New) A method for binding Grb2 comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 1.

30. (New) A method of inhibiting activation of Ras comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 1.

31. (New) A method of treating breast cancer comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 1.

32. (New) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 1, in an amount effective to bind to Grb2.

33. (New) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 1, in an amount effective to inhibit Ras activity.

34. (New) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 1, in an amount effective to treat breast cancer.

35. (New) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 22, in an amount effective to bind to Grb2.

36. (New) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 22, in an amount effective to inhibit Ras activity.

37. (New) A composition comprising a pharmaceutically acceptable carrier, and a pseudopeptide according to claim 22, in an amount effective to treat breast cancer.

38. (New) A method for binding Grb2 comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 1, selected from the group consisting of:

-mAZ-pTyr-(αMe)pTyr-Asn-NH_2

- mAZ-pTyr-(αMe)pTyr-Asn-Aha-Antennapedia

- mAZ-Pmp-(αMe)pTyr-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(COOH)-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(CH_2-COOH)-Asn-NH_2

- mAZ-pTyr-(αMe)Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)F_2Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(PO_3H_2)Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(PO_3H_2)-Asn-Aha-Antennapedia.

39. (New) A method of inhibiting Ras activity comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 1, selected from the group consisting of:

-mAZ-pTyr-(αMe)pTyr-Asn-NH_2

- mAZ-pTyr-(αMe)pTyr-Asn-Aha-Antennapedia

- mAZ-Pmp-(αMe)pTyr-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(COOH)-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(CH_2-COOH)-Asn-NH_2

- mAZ-pTyr-(αMe)Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)F_2Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(PO_3H_2)Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(PO_3H_2)-Asn-Aha-Antennapedia.

40. (New) A method of treating breast cancer comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 1, selected from the group consisting of:

-mAZ-pTyr-(αMe)pTyr-Asn-NH_2

- mAZ-pTyr-(αMe)pTyr-Asn-Aha-Antennapedia

- mAZ-Pmp-(αMe)pTyr-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(COOH)-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(CH_2-COOH)-Asn-NH_2

- mAZ-pTyr-(αMe)Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)F_2Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(PO_3H_2)Pmp-Asn-NH_2

- mAZ-pTyr-(αMe)Phe(PO_3H_2)-Asn-Aha-Antennapedia.

41. (New) A method for binding Grb2 comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 22.

42. (New) A method of inhibiting activation of Ras comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 22.

43. (New) A method of treating breast cancer comprising administering to a patient in need thereof an effective amount of a pseudopeptide according to claim 22.